Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:activeIngredient |
inactivated hepatitis A virus
|
| gptkbp:age |
adults
children |
| gptkbp:approvalYear |
1995
|
| gptkbp:approvedBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:ATCCode |
gptkb:J07BC02
|
| gptkbp:broadcastOn |
two-dose series
|
| gptkbp:contraindication |
hypersensitivity to any component
|
| gptkbp:countryOfOperation |
gptkb:United_Kingdom
gptkb:United_States |
| gptkbp:form |
suspension for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Havrix
|
| gptkbp:indication |
immunization against hepatitis A
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
nausea
fatigue headache loss of appetite injection site soreness |
| gptkbp:storage |
2°C to 8°C
|
| gptkbp:usedFor |
prevention of hepatitis A
|
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:hepatitis_A_vaccine
gptkb:Hepatitis_A_vaccine gptkb:Epaxal |
| gptkbp:bfsLayer |
7
|